Safety profile of lutetium-177 in patients with impaired renal function: A retrospective analysis of adverse events in mCRPC treatment. Dr. Saylani highlighted that Lutetium-177 vipivotide tetraxetan ...

Exploratory outcome measures include health-related quality of life, overall survival, and biomarker assessments. A broad cross-section of geographically and socioeconomically diverse clinical sites ...

The primary study objective was to evaluate the prognostic value of post-therapeutic SPECT by RECIP 1.0 for overall survival.

From 1,085 citations identified, 48 studies with 15,368 men with mCRPC met inclusion criteria. Most studies were retrospective cohorts (n = 39) from Europe (n = 22) and North America (n = 18), with ...

(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA was host to the Keynote Presentation. Dr. William Dahut discussed how ...

Annual Symposium held in San Francisco, CA between February 13–15, 2025 was host to a prostate cancer poster session. Dr. Ida Sonni presented a study evaluating the diagnostic performance of 18 ...

Patients with mHSPC benefited from darolutamide + ADT + docetaxel irrespective of age (<75 years and ≥75 years), with consistent improvements in overall survival, time to mCRPC, and time to initiation ...

In Meraouna et al.'s study, the failure-free survival rate was 66% at 3 years of follow-up. Regarding treatment-related morbidities, 12.3% of patients experienced grade 3 genitourinary (GU) toxicity, ...

In the post-op SAKK 09/10 trial, only patients in the higher PORTOS score group benefited from radiation therapy dose escalation (clinical progression free survival HR 0.19, 95% CI 0.05-0.70; p = 0.01 ...

After re-staging patients, ideally with PSMA-PET, and performing a biopsy to confirm the recurrence and stratify them into risk categories, it is time to discuss local salvage treatment. Options ...

The primary endpoint is objective response rate, with progression-free survival a key secondary endpoint. The study includes a pre-registration step for arm determination by the molecular tumor board.

Annual Symposium held in San Francisco, CA between February 13–15, 2025 was host to prostate cancer poster session. Dr. Zachary Klaassen presented the results of a population-based analysis evaluating ...